Teacher Retirement System of Texas purchased a new stake in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,961 shares of the biopharmaceutical company’s stock, valued at approximately $458,000.
Other institutional investors also recently bought and sold shares of the company. Chartwell Investment Partners LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $1,374,000. Hamilton Lane Advisors LLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter valued at $7,594,000. OxFORD Asset Management LLP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $715,000. Rothschild Asset Management Inc. purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $1,124,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Esperion Therapeutics by 34.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 91,843 shares of the biopharmaceutical company’s stock valued at $4,604,000 after acquiring an additional 23,568 shares in the last quarter. Institutional investors and hedge funds own 91.69% of the company’s stock.
Several equities analysts have recently commented on ESPR shares. Citigroup cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and boosted their price target for the company from $77.00 to $96.00 in a report on Monday, January 22nd. Chardan Capital boosted their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th. UBS set a $88.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. BidaskClub cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Stifel Nicolaus set a $105.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Monday, January 15th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Esperion Therapeutics has an average rating of “Buy” and a consensus price target of $87.36.
Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) opened at $76.53 on Friday. Esperion Therapeutics Inc has a fifty-two week low of $20.39 and a fifty-two week high of $82.68.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.36. During the same quarter in the prior year, the firm earned ($1.29) earnings per share. equities research analysts predict that Esperion Therapeutics Inc will post -5.66 earnings per share for the current fiscal year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the completion of the transaction, the director now owns 3,177 shares of the company’s stock, valued at approximately $228,076.83. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 32.50% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/17/teacher-retirement-system-of-texas-invests-458000-in-esperion-therapeutics-inc-espr.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.